Merck Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma
Darmstadt, Germany (ots/PRNewswire) - - First patient begins treatment in an international Phase II study investigating the efficacy and safety of MSB0010718C in patients with metastatic Merkel cell carcinoma (mMCC) - mMCC is a rare and aggressive skin cancer lacking effective treatments - MSB0010718C is also ...